LCTX vs XERS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
XERS Captures Institutional Edge (3โ1 Pillars ยท 4โ6 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xeris Biopharma Holdings, Inc. Common Stock (XERS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while LCTX counters with relative strength in Valuation. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus XERS at 62.3x Forward P/E and 12.7% operating margin (+44.2% YoY). In options structure, LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against XERS sits in SURGE (12th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LCTX Revenue | XERS Revenue | LCTX Op. Margin | XERS Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -837.9% | N/A | LCTX |
| FY2019 | $0M | N/A | -1106.0% | N/A | LCTX |
| FY2020 | $0M | $20M | -1448.4% | -414.5% | XERS |
| FY2021 | $0M | $50M | -1133.6% | -232.2% | XERS |
| FY2022 | $10M | $110M | -153.2% | -74.3% | XERS |
| FY2023 | $10M | $160M | -276.5% | -26.8% | XERS |
| FY2024 | $10M | $200M | -226.1% | -16.6% | XERS |
| FY2025 | $10M | $290M | -251.6% | 8.5% | XERS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LCTX | XERS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $212.1M | $3.1B | Larger Scale | XERS |
| Trailing P/E Ratio Valuation | 30.7x | 86.2x | Lower Multiple | LCTX |
| Forward P/E Ratio Valuation | 30.7x | 62.3x | Lower Multiple | LCTX |
| Revenue Growth (YoY) Growth | -61.0% | +44.2% | Higher Growth | XERS |
| Operating Margin (TTM) Profitability | -280.3% | 12.7% | Higher Margin | XERS |
| Net Profit Margin Profitability | 16.2% | -1.8% | Higher Margin | LCTX |
| Return on Equity (ROE) Capital Efficiency | 4.3% | -27.1% | Higher ROE | LCTX |
| 52-Week Range Position Momentum | 4% ($1โ$2) | 94% ($5โ$17) | Stronger Trend | XERS |
| Beta / 30D Volatility Risk Regime | 1.36ฮฒ ยท 79% Vol | -0.03ฮฒ ยท 104% Vol | Lower Realized Risk | LCTX |
| Unified Institutional Score Composite Signal | 58.9 / 100 (HOLD) | 36.5 / 100 (SELL) | Higher Composite | LCTX |